Email this article THE POSSIBILITIES AND MECHANISMS OF ACTION OF HORMONE THERAPY FOR CASTRATION-RESISTANT PROSTATE CANCER
- Authors: Alekseev B.Y.1, Andrianov A.N.1
-
Affiliations:
- P.A. Herzen Moscow Oncology Research Institute
- Issue: Vol 9, No 1 (2013)
- Pages: 68-73
- Section: REVIEW
- Published: 30.03.2013
- URL: https://oncourology.abvpress.ru/oncur/article/view/197
- DOI: https://doi.org/10.17650/1726-9776-2013-9-1-68-73
- ID: 197
Cite item
Full Text
Abstract
Hormone therapy is a basic treatment for locally advanced and/or metastatic prostate cancer (PC); however, most patients become resistant to first-line therapy in the course of time. Abiraterone is a highly active, selective, irreversible CYP17 inhibitor that prevents the conversion of pregnenolone to dehydroepiandrostenedione and that of progesterone to androstenedione in the testes and adrenals, as well as directly in tumor tissue. This drug is able to considerably improve tumor-specific and overall survival rates in patients with castration-resistant PC (CRPC) and it has been approved by the U.S. Food and Drug Administration to treat this cohort of patients. Despite the efficacy of abiraterone, which has been proven during clinical trials, the disease progresses over time. This literature review deals with the possible mechanisms of resistance to abiraterone. A deep insight into the above mechanisms can open up fresh opportunities for resistance control and improve survival rates in patients with CRPC.
About the authors
B. Ya. Alekseev
P.A. Herzen Moscow Oncology Research Institute
Email: mailandrianov@gmail.com
Russian Federation
A. N. Andrianov
P.A. Herzen Moscow Oncology Research Institute
Author for correspondence.
Email: mailandrianov@gmail.com
Russian Federation
References
Supplementary files
